Tag: Hatch-Waxman Act
Generic drugs saved the U.S. healthcare system $3.4 trillion from 2015-2024. Learn how Hatch-Waxman, biosimilars, and market competition drive these massive savings and what challenges remain.
Explore how the FDA approves generic drugs via the ANDA process, ensuring safety and savings. Learn about bioequivalence standards, GDUFA timelines, and the impact of the Hatch-Waxman Act on your medication.
Medications
Archives
Recent-posts
Generic Drug Quality Issues: Manufacturing Plant Problems Explained
Aug, 17 2026
OTC Medication Safety in Pregnancy: Essential Questions to Ask Your Doctor
Aug, 27 2026
How to Talk to Your Pharmacist About Expired Drugs: Safety, Risks & Disposal
Jul, 9 2026
False Advertising in Generics: Legal Risks and Rules You Can't Ignore
Nov, 24 2025
Biologic Patent Protection: When Biosimilars Can Enter the Market
Aug, 12 2026